🔗 Share this article The Global Health Body Raises Concern Over Acute Lack of Weight-Loss Injections Under one in 10 individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it releases its inaugural recommendations on the therapies. Given more than one billion individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to these injectable treatments. Per estimates, more than two billion could be obese by 2030 if no action is taken. "Our new guidance affirms that obesity is a lifelong illness that can be treated with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are key obstacles to widespread availability to the treatments that can help people shift substantial body mass, notes the organization. Skinny Jab Shortage Even in the present best projected outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, as stated by the WHO. The guideline urges countries and companies to expand availability, via strategies such as licensing agreements. A patent on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in several countries in 2026. The Way Obesity Jabs Operate These medications mimick a biological compound to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake. Individuals usually start to lose weight after several weeks of commencing the once-weekly jabs. Evidence suggests people may see weight return within a year of discontinuing the treatment, when their normal food cravings resume. To be above a healthy weight increases your risk for contracting medical conditions, including diabetes, heart disease, brain attack, and some cancers. Excess weight impacts individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
Under one in 10 individuals eligible to benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it releases its inaugural recommendations on the therapies. Given more than one billion individuals worldwide currently classified as obese, it is advocating for broader and more equitable availability to these injectable treatments. Per estimates, more than two billion could be obese by 2030 if no action is taken. "Our new guidance affirms that obesity is a lifelong illness that can be treated with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are key obstacles to widespread availability to the treatments that can help people shift substantial body mass, notes the organization. Skinny Jab Shortage Even in the present best projected outlook, the manufacturing of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, as stated by the WHO. The guideline urges countries and companies to expand availability, via strategies such as licensing agreements. A patent on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in several countries in 2026. The Way Obesity Jabs Operate These medications mimick a biological compound to delay gastric emptying, curb appetite and enhance satiety so users reduce food intake. Individuals usually start to lose weight after several weeks of commencing the once-weekly jabs. Evidence suggests people may see weight return within a year of discontinuing the treatment, when their normal food cravings resume. To be above a healthy weight increases your risk for contracting medical conditions, including diabetes, heart disease, brain attack, and some cancers. Excess weight impacts individuals in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.